Indivior Pharmaceuticals, Inc.
INDV· Nasdaq
INDVIndivior Pharmaceuticals, Inc.
Filed Feb 26, 2026 · 10-K · 57 days after period end · 0001628280-26-012237
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024 |
|---|---|---|
| Revenue | $357.00M | $298.00M |
| Net Income | $103.00M | $21.00M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Indivior Pharmaceuticals, Inc. · CIK 1625297 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Feb 26, 2026 · 57 d after period end
